These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 15832429)
21. Liver transplantation for patients with pulmonary tuberculosis. Wang B; Lu Y; Yu L; Liu C; Liu X; Wu Z; Zhu HT; Pan CE Transpl Infect Dis; 2009 Apr; 11(2):128-31. PubMed ID: 19210689 [TBL] [Abstract][Full Text] [Related]
22. Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Chang KC; Leung CC; Yew WW; Tam CM Eur Respir J; 2007 Feb; 29(2):347-51. PubMed ID: 17005575 [TBL] [Abstract][Full Text] [Related]
23. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488 [TBL] [Abstract][Full Text] [Related]
24. Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Tostmann A; Boeree MJ; Harries AD; Sauvageot D; Banda HT; Zijlstra EE Trop Med Int Health; 2007 Jul; 12(7):852-5. PubMed ID: 17596252 [TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Chien JY; Huang RM; Wang JY; Ruan SY; Chien YJ; Yu CJ; Yang PC Int J Tuberc Lung Dis; 2010 May; 14(5):616-21. PubMed ID: 20392356 [TBL] [Abstract][Full Text] [Related]
26. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. Kuaban C; Bercion R; Koulla-Shiro S East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Risk Factors for Development of Anti-Tubercular Therapy Induced Hepatotoxicity: A Prospective Study. Subbalaxmi MVS; Soanker R; Lakshmi AV Curr Drug Saf; 2020; 15(3):198-204. PubMed ID: 32589563 [TBL] [Abstract][Full Text] [Related]
28. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968 [TBL] [Abstract][Full Text] [Related]
29. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920 [TBL] [Abstract][Full Text] [Related]
30. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. Hassen Ali A; Belachew T; Yami A; Ayen WY PLoS One; 2013; 8(5):e64622. PubMed ID: 23696901 [TBL] [Abstract][Full Text] [Related]
31. Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity. Wu S; Wang YJ; Tang X; Wang Y; Wu J; Ji G; Zhang M; Chen G; Liu Q; Sandford AJ; He JQ PLoS One; 2016; 11(6):e0157478. PubMed ID: 27281183 [TBL] [Abstract][Full Text] [Related]
32. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection. Liu S; He Z; Wu W; Jin H; Cui Y Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751 [TBL] [Abstract][Full Text] [Related]
33. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Pukenyte E; Lescure FX; Rey D; Rabaud C; Hoen B; Chavanet P; Laiskonis AP; Schmit JL; May T; Mouton Y; Yazdanpanah Y Int J Tuberc Lung Dis; 2007 Jan; 11(1):78-84. PubMed ID: 17217134 [TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus and hepatitis B virus co-infections among tuberculosis patients attending a Model Rural Health Research Unit in Ghatampur, North India. Hussain T; Kulshreshtha KK; Yadav VS; Katoch K Indian J Med Microbiol; 2015; 33(4):496-502. PubMed ID: 26470954 [TBL] [Abstract][Full Text] [Related]
35. Prophylactic antiviral treatment reduces the incidence of liver failure among patients coinfected with Mycobacterium tuberculosis and hepatitis B virus. Lian J; Hu P; Lu Y; Liu Y; Wang X; Zhang Y; Jia H; Yang Y Virus Res; 2019 Sep; 270():197664. PubMed ID: 31315023 [TBL] [Abstract][Full Text] [Related]
36. [Diagnosis of liver diseases in patients with pulmonary tuberculosis]. El'kin AV; Ariél' BM; Nechaev VV Probl Tuberk; 1992; (7-8):15-8. PubMed ID: 1488430 [TBL] [Abstract][Full Text] [Related]
37. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China. Wu S; Xia Y; Lv X; Zhang Y; Tang S; Yang Z; Tu D; Deng P; Cheng S; Wang X; Yuan Y; Liu F; Hu D; Zhan S BMC Public Health; 2012 Jun; 12():454. PubMed ID: 22712786 [TBL] [Abstract][Full Text] [Related]
38. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985 [TBL] [Abstract][Full Text] [Related]
39. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
40. The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study. Song JH; Yoon SY; Park TY; Heo EY; Kim DK; Chung HS; Lee JK Respir Res; 2019 Dec; 20(1):283. PubMed ID: 31842883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]